CLAIMS

1. A cell of the haematopoietic lineage, that is derived from an induced pluripotent stem cell comprising a controllable transgene for conditional immortalisation.
2. A cell of the haematopoietic lineage according to claim 1, wherein the cell is:
   a CD34+ CD43+ haematopoietic stem cell;
   a CD4+ T cell;
   a CD8+ T cell;
   a regulatory T cell;
   a $CD56^{high}CD16^{\pm}$ Natural Killer cell;
   a $CD56^{low}CD16^{high}$ Natural Killer cell;
   a CD19+ B cell;
   a myeloid dendritic cell;
   a plasmacytoid dendritic cell;
   a neutrophil; or
   a CD34+CD49f+CD90+CD38-CD45RA- Long Term HSC.
3. A cell of the haematopoietic lineage according to claim 1, wherein the cell is a Myeloblast, Lymphoblast, Megakaryocyte, Thrombocyte, Erythrocyte, Mast cell, Basophil, Neutrophil, Eosinophil, Monocyte, Macrophage, $CD56^{DIM}$ Natural Killer cell, $CD56^{BRIGHT}$ Natural Killer Cell, $CD56^{high}CD16^{\pm}$ Natural Killer Cell, $CD56^{low}CD16^{high}$ Natural Killer cell, Natural Killer T (NKT) cell, NKT cell expressing CD161, CD4+ T cell, CD8+ T cell, memory T cell, B-2 cell, B-1 cell, memory B cell, plasma B cell, myeloid Dendritic Cell, or plasmacytoid DC.
4. A cell of the haematopoietic lineage according to any of claims 1 to 3, wherein the pluripotent stem cell is obtainable or obtained from a conditionally-immortalised cell or a conditionally immortalised stem cell.
5. A cell of the haematopoietic lineage according to any of claims 1 to 4, wherein the pluripotent stem cell is obtainable or obtained by reprogramming a conditionally-immortalised stem cell with one or more transcription factors.
6. A cell of the haematopoietic lineage according to any preceding claim, wherein the pluripotent stem cell according comprises the C-MYC-ER fusion protein.
7. A cell of the haematopoietic lineage according to any preceding claim, wherein the pluripotent stem cell comprises the c-mycER transgene, optionally in its genome.
8. A cell of the haematopoietic lineage according to any preceding claim, wherein the pluripotent stem cell is obtainable or obtained from a conditionally-immortalised neural stem cell.
9. A cell of the haematopoietic lineage according to any preceding claim, wherein the pluripotent stem cell according to any preceding claim, which is obtainable or obtained from a conditionally-immortalised stem cell line.

10. A cell of the haematopoietic lineage according to claim 9, wherein the stem cell line is CTX0E03 having ECACC Accession No. 04091601 or STR0C05 having ECACC Accession No. 04110301.
11. A cell of the haematopoietic lineage according to any preceding claim, wherein the cell is a haematopoietic stem cell that expresses one or more markers of haematopoietic differentiation.
12. A method of producing a cell of haematopoietic lineage from a pluripotent stem cell, comprising the steps of (i) reprogramming a conditionally-immortalised stem cell to form a pluripotent cell; and (ii) differentiating the pluripotent cell into a cell of the haematopoietic lineage.
13. A method according to claim 12, wherein the reprogramming step comprises introducing one or more of the transcription factors OCT4, L-MYC, KLF4 and SOX2, and optionally the RNA-binding LIN28, into the conditionally-immortalised stem cell.
14. A method according to claim 13, wherein:
    the introduced transcription factor comprises or consists of OCT4;
    the introduced transcription factors comprise or consist of OCT4 and SOX2;
    the introduced transcription factors comprise or consist of OCT, KLF4 and SOX2;
    the introduced transcription factors comprise or consist of OCT4, KLF4, SOX2 and MYC; or
    MYC activity is provided to promote the reprogramming process by the provision of 4-OHT in the medium to activate a c-myc-ER^{TAM} transgene in the stem cell to be reprogrammed.
15. A method according to claim 13 or claim 14, wherein the transcription factors and optional LIN28 are introduced into the conditionally-immortalised stem cell using one or more episomal plasmids, one or more viral vectors optionally selected from lentivirus, retrovirus or Sendai-virus, or by mRNA transfection.
16. A method according to any of claims 12 to 15, wherein the differentiation step comprises a step of differentiating the pluripotent cell to an HSC and optionally further down the lineage.
17. A method according to claim 16, wherein the pluripotent cell is differentiated into an HSC by (i) culturing in a medium comprising activin A, VEGF, SCF and BMP4 to form mesodermal cells and then (ii) culturing the mesodermal cells in the presence of FLT3, SCF, BMP-4, and interleukins 3 and 6, to form the HSCs.
18. A method according to claim 16 or claim 17, wherein the HSCs are differentiated towards a T lymphocyte fate by (i) providing DLL-1 or DLL-4 protein in the culture to activate NOTCH signalling in the HSCs; or (ii) co-culturing the HSCs with stromal cells, optionally engineered to express the Notch ligand DLL1 or (iii) culturing the HSCs on a monolayer of bound VCAM and DLL4 proteins.

19. A method according to any of claims 12 to 18, wherein the haematopoietic lineage differs from the lineage of the conditionally-immortalised stem cell that was reprogrammed.
20. A method according to any of claims 12 to 19, wherein the cell of haematopoietic lineage is as defined in claim 2 or claim 3.
21. A method according to any of claims 12 to 20, comprising the step of reactivating the conditionally-immortalised phenotype of the cell of haematopoietic lineage that results from the method.
22. A method according to any of claims 12 to 21, wherein the conditionally-immortalised stem cell that is reprogrammed, is as defined in any of claims 4 to 10.
23. A method according to any of claims 12 to 22, comprising one or more steps selected from:

culturing the cells that result from the method;

passaging the cells that result from the method;

harvesting or collecting the cells that result from the method;

packaging the cells that result from the method into one or more containers; and/or formulating the cells that result from the method with one or more excipients, stabilisers or preservatives.

24. A cell of haematopoietic lineage obtained or obtainable by the method of claims 12 to 23.
25. An extracellular vesicle produced by the cell of any of claims 1 to 11, or 24.
26. An extracellular vesicle according to claim 25, which is an exosome.
27. A pharmaceutical composition comprising a cell according to any of claims 1 to 11, or 24 or an extracellular vesicle according to claim 25 or claim 26, and one or more pharmaceutically-acceptable excipients.
28. A pharmaceutical composition according to claim 27, which is frozen, cryopreserved or lyophilised.
29. A cell according to claim 24, a extracellular vesicle according to claim 25 or 26, or a pharmaceutical composition according to claim 27 or claim 28, for use in a method of treating a disease or disorder in a patient in need thereof, optionally wherein the disease or disorder is a cancer, an autoimmune disease or an infection, optionally wherein the infection is viral and optionally wherein the virus is a coronavirus or other respiratory tract viral infection.